MindBio Therapeutics Files Patent Applications for AI-Driven Voice-Based Intoxication Detection

MindBio Therapeutics Corp. (CSE: MBIO) (OTCQB: MBQIF) has moved to formalize its intellectual property position in AI-driven intoxication detection, filing patent applications tied to 15 novel discoveries in the relationship between speech patterns and the effects of neurologically active substances. The company, which is commercializing AI-driven voice technology for drug and alcohol intoxication detection, announced the filings in a recent company update.

The patent applications center on a machine learning model designed to detect drug and alcohol impairment using short voice samples. This approach departs from conventional methods, such as blood, urine, or saliva tests, which can be costly and time-consuming. By analyzing speech patterns, the platform can estimate impairment without requiring physical samples, offering a non-invasive and efficient alternative for high-volume, regulated environments.

Initial commercial rollout is targeting the mining and aviation industries via Edge AI kiosk systems. These sectors often require frequent and reliable testing to ensure safety, and the technology is designed to integrate seamlessly into existing workflows. Broader applications include call centers, law enforcement, and mental health screening, where quick and accurate impairment detection can enhance safety and productivity.

The overall global drug and alcohol testing market is projected to reach $4.2 billion by 2033, highlighting the growing demand for innovative testing solutions. MindBio Therapeutics' technology aims to capture a share of this market by addressing the limitations of current testing methods, particularly in environments where testing is costly and time-consuming.

For more information about MindBio Therapeutics, visit the company's newsroom at https://ibn.fm/MBQIF.

InvestorWire, a specialized communications platform, distributed this press release. It is part of the Dynamic Brand Portfolio @ IBN that provides access to a vast network of wire solutions, article and editorial syndication to 5,000+ outlets, enhanced press release enhancement, social media distribution, and tailored corporate communications solutions. For more information, visit https://www.InvestorWire.com.